Valuation: Orexo AB

Market Cap 520M 54.88M 47.49M 44.48M 40.6M 76.42M 5.23B 77.7M 204M 2.62B 206M 202M 8.8B P/E 2026 *
-1.42x
P/E 2027 * -2.05x
Enterprise Value 415M 43.81M 37.91M 35.51M 32.4M 61M 4.17B 62.02M 163M 2.09B 164M 161M 7.02B EV / Sales 2026 *
21.9x
EV / Sales 2027 * 13.7x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-12.43%
1 month-26.19%
3 months-26.19%
6 months-52.01%
Current year-52.01%
1 month 1.55
Extreme 1.55
1.77
Current year 1.55
Extreme 1.55
2.29
1 year 1.55
Extreme 1.55
3.23
3 years 1.08
Extreme 1.08
3.23
5 years 1.04
Extreme 1.04
4.02
10 years 1.04
Extreme 1.04
7.7
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-12.43%-.--% - - 54.09M
+1.82%+0.55%+62.25%+23.39% 317B
-0.10%+0.24%+32.75%-11.50% 72.2B
-0.48%+24.33%+63.15%+140.72% 11.7B
+0.63%+0.31%-3.74%-4.44% 8.45B
+3.86%+12.28%-10.94%-10.67% 4.75B
-0.47%+21.53%+3.76%+49.73% 4.38B
+1.74%+11.56%-26.79%+10.24% 4.26B
-1.20%+5.47%+14.16%+54.18% 2.77B
+0.80%+1.11%+1.98%+1.03% 2.26B
Average -0.58%+8.82%+15.18%+28.08% 47.56B
Weighted average by Cap. +1.38%+2.58%+53.07%+20.01%

Financials

2026 *2027 *
Net sales 19M 2M 1.73M 1.62M 1.48M 2.79M 191M 2.84M 7.45M 95.55M 7.52M 7.36M 321M 27.5M 2.9M 2.51M 2.35M 2.15M 4.04M 276M 4.11M 10.79M 138M 10.88M 10.65M 465M
Net income -375M -39.55M -34.23M -32.06M -29.26M -55.08M -3.77B -56M -147M -1.89B -148M -145M -6.34B -270M -28.53M -24.69M -23.12M -21.1M -39.73M -2.72B -40.39M -106M -1.36B -107M -105M -4.57B
Net Debt -105M -11.08M -9.58M -8.98M -8.19M -15.42M -1.05B -15.68M -41.19M -528M -41.53M -40.66M -1.78B -143M -15.08M -13.05M -12.22M -11.16M -21M -1.44B -21.35M -56.1M -719M -56.56M -55.38M -2.42B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise